For the first time, the premier bioengineering event that gathers national and international industry leaders is highlighting phage therapy as a “next generation antimicrobial”

Winnipeg, October 4, 2024. - TheNewswire - Cytophage Technologies (TSXV:CYTO) (“Cytophage” or the “Company”), the only publicly traded phage company that is focused on bacteriophage solutions for both animal health and human health, today announced that its CEO, Dr. Steven Theriault, has been invited to participate in this year’s Canada SynBio Conference. Discussing the topic “Reshaping Healthcare – The Future of Phage Therapies”, Dr. Theriault and Dr. Jessica Sacher, a staff scientist at the renowned Bollyky Lab at Stanford University, are responding to the growing awareness among public and private sector leaders in bioengineering that bacteriophages could be the “next generation of antimicrobials”. They will discuss the cutting-edge techniques used to create effective phages and address the challenges, breakthroughs and future of phage therapy. The session is scheduled for October 8th at the MaRS Discovery District in downtown Toronto.

The Canada SynBio Conference, hosted by Ontario Genomics, a not-for-profit that has received over $1.49B in public and private funding, works to catalyze ground-breaking research in real-world human health solutions. The 6th annual conference is sponsored by numerous leaders in Canada’s microbiology sector including Genome Canada, BIOTECanada, Northeastern University, and the Concordia Genome Foundry. Over 350 representatives from academia, industry, not-for-profits and government are expected to attend.

Cytophage CEO Dr. Steven Theriault commented: “Being invited to speak at this conference represents a palpable shift in the public mindset on the possibilities that phage therapy can provide for healthcare. It’s a clear recognition that a phage company like Cytophage can play a leading role in combatting antimicrobial resistance (AMR). I am truly honoured to engage in this session with my colleague, Dr. Sacher, who is currently working on establishing a new phage center at Stanford University. Together, we are taking this opportunity to directly engage with representatives from both the public and private sectors to provide insights on the latest advancements in phage therapy and spread the word that feasible and widely applicable phage treatment options already exist.”

About SynBio Conference

2024 Canada SynBio Conference is Canada’s premier synthetic biology event that brings together national and international leaders in the field of engineering biology to foster inter-sector partnerships and contribute to establishing Canada as a global powerhouse in the bioeconomy.

 

This year's conference program will feature a wide range of topics, including cellular agriculture, circular economy, biomanufacturing, ethical and regulatory frameworks, training, and health innovations in addition to interactive workshops and networking events.

    

For further information please contact:

 

Heather Medwick

Chief Operating Officer

heather@cytophage.com

431 388 8873

Cytophage Investor Alerts: https://cytophage.com/subscribe/

  

About Cytophage Technologies

 

Cytophage Technologies (TSXV:CYTO) is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization. Committed to addressing the global challenge of antibiotic resistance, Cytophage advances innovative products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health, and food security.

 

Cautionary Statement on Forward-Looking Information

 

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Cytophage to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Cytophage’s Filing Statement dated January 30, 2024, which is available for view on SEDAR+ at www.sedarplus.ca. These risks include but are not limited to, the risks associated with the bacteriophage industry, such as operational risks in development or capital expenditures, the uncertainty of extensive regulatory approval requirements, government regulations, protection of intellectual property, product liability and rapid technological advancements. Forward-looking statements contained herein are made as of the date of this press release, and Cytophage disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.

 

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.